Drug updated on 4/29/2024
| Dosage Form | Injection (subcutaneous; 94.5 mg/0.5 mL) |
| Drug Class | HAO1-directed small interfering ribonucleic acids |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Oxlumo (lumasiran) Prescribing Information. | 2023 | Alnylam Pharmaceuticals, Inc., Cambridge, MA |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. | Data not availableSubjects F: null% M: null% | 2023 | Pediatric Nephrology |
| Lumasiran for advanced primary hyperoxaluria type 1: Phase 3 ILLUMINATE-C trial. | Data not availableSubjects F: null% M: null% | 2023 | American Journal of Kidney Diseases |
| Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. | Data not availableSubjects F: null% M: null% | 2022 | Genetics in Medicine |
| Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. | Data not availableSubjects F: null% M: null% | 2021 | The New England Journal of Medicine |
Sex Distribution:
Year:
2023
Source:Pediatric Nephrology
Sex Distribution:
Year:
2023
Source:American Journal of Kidney Diseases
Document Title
Sex Distribution:
Year:
2022
Source:Genetics in Medicine
Sex Distribution:
Year:
2021
Source:The New England Journal of Medicine
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. | 2023 | Nature Reviews Nephrology |